FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in general, to molecules, which specifically interact with 41BB – a representative of TNF receptor superfamily (hereinafter – TNFRSF), in particular to multivalent and/or multi-specific molecules, which bind at least 41BB. Fused proteins, according to the invention, are capable of enhanced clustering of TNFRSF representatives compared to bivalent antibodies, without crosslinking.
EFFECT: fused proteins, according to the invention, modulate immune cells, and they are suitable for use in the treatment of neoplasms, inflammatory pathological conditions.
16 cl, 25 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES | 2020 |
|
RU2818588C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| PARTICLES CONJUGATED TO PEPTIDE | 2014 |
|
RU2813163C2 |
| MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS THAT BIND TO DR5 | 2016 |
|
RU2748620C2 |
| TNF RECEPTOR-BINDING AGONISTS | 2016 |
|
RU2821343C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
